Burden of Oral Mucositis: A Systematic Review and Implications for Future Research
Open Access
- 3 May 2018
- journal article
- review article
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 41 (6) , 399-405
Abstract
Background: Surprisingly little is known about the burden of oral mucositis (OM). We provide a systematic review of studies on the burden of OM (incidence, economic impact, health-related quality of life (HRQoL)). Methods: Systematic literature searches were made in BIOSIS, EMBASE, and MEDLINE. Inclusion criteria were studies on OM in hematology/oncology patients of ≥ 18 years, journal articles, English language, and published between 2000 and 2016; OM treatment studies were excluded. Quality assessment was performed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: We screened 4,996 hits, and identified 68 studies of which 13 were without transparency on OM grading. The evidence level of 65 studies was rated ‘low' or ‘very low' in 58.5%, ‘moderate' in 20% and ‘high' in 21.5%. Mean value of incidence (7 studies) was 83.5% for all grades of OM with hematopoietic stem cell transplantation. OM incidence for all grades in head and neck cancer patients was 59.4-100%. Considering the economic impact, 16 studies showed highly variable numbers. HRQoL was measured in 16 studies using 13 different instruments. Statistically significant changes in HRQoL scores were demonstrated. Conclusion: OM is common, burdensome, costly and imposes major reductions in HRQoL. However, from a quality standpoint, the level of current evidence in OM is disappointing. The field needs continued attention to address methodological challenges.Keywords
This publication has 72 references indexed in Scilit:
- A Prospective Study Comparing the Outcomes and Health-Related Quality of Life in Adult Patients with Myeloid Malignancies Undergoing Allogeneic Transplantation Using Myeloablative or Reduced-Intensity ConditioningTransplantation and Cellular Therapy, 2012
- Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and SpainLung Cancer, 2011
- Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomasSupportive Care in Cancer, 2011
- Management of oral and gastrointestinal mucositis: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2011
- A comparison of oral mucositis in allogeneic hematopoietic stem cell transplantation between conventional and reduced-intensity regimensSupportive Care in Cancer, 2011
- Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapySupportive Care in Cancer, 2011
- Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumorsSupportive Care in Cancer, 2011
- Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinibBritish Journal of Cancer, 2009
- Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of lifeSupportive Care in Cancer, 2009
- The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCTBone Marrow Transplantation, 2008